Showing 15 posts of 128 posts found.


Celgene bucks trend to strengthen neuroscience pipeline

March 21, 2018
Research and Development, Sales and Marketing Alzheimer's, Celgene, Prothena, biotech, drugs, neuroscience, pharma, pharmaceutical

Celgene has gone against industry movement to back out of the neuroscience area by putting down a potential $2.2 billion …


Celgene strikes $101m partnership in oncology, neurodegenerative and inflammatory

March 5, 2018
Research and Development, Sales and Marketing Cancer, Celgene, Vividion, inflammatory, neurodegenerative, oncology, pharma

Celgene has inked a new multi-year partnership with biotech firm Vividion Therapeutics to leverage the latter’s proteomics and chemistry platforms …


FDA refuses to review Celgene’s ozanimod in multiple sclerosis

February 28, 2018
Research and Development, Sales and Marketing Celgene, FDA, multiple sclerosis, ozanimod, pharma

Celgene has been dealt a heavy blow, revealing that the FDA has rejected its New Drug Application for its sphingosine …


Celgene reveals strong P3 Otezla data in rare inflammatory condition

February 19, 2018
Research and Development, Sales and Marketing Behçet's disease, Celgene, apremilast, otezla, pharma

Celgene has lifted the curtain on strong new Phase 3 data for its phosphodiesterase 4 (PDE4) inhibitor Otezla (apremilast) in …


Silicon Valley-backed Celgene spin-off launches with $250m

February 16, 2018
Medical Communications, Sales and Marketing Celgene, Celularity, biotech, drugs, pharma, pharmaceutical

Biotechs are known for getting off the ground early with serious levels of financing, often based more on the acumen …


Celgene Executive Chairman Bob Hugin to retire

January 30, 2018
Manufacturing and Production, Medical Communications Bob Hugin, Celgene, pharma

Fresh from its acquisition of Juno Therapeutics, Celgene has announced that its Executive Chairman Bob Hurgin is to retire effective …


Celgene confirms rumours, with $9bn deal for Juno

January 22, 2018
Manufacturing and Production, Sales and Marketing CAR-T, Celgene, biotech, drugs, juno therapeutics, pharma, pharmaceutical

It seems like 2018 may well be the year for M&A that everyone had expected, as two major deals on …


Celgene rumoured to be revving up for Juno buyout

January 17, 2018
Research and Development, Sales and Marketing CAR-T, Celgene, Juno, biotech, drugs, pharma, pharmaceutical

Celgene has already started off the year with a bang, announcing a deal with Impact Biomedicines worth a potential $7 …


Celgene in $7bn shot on Impact

January 8, 2018
Sales and Marketing Celgene, Impact Biomedicines, biotech, drugs, pharma, pharmaceutical

Billions of dollars do not often get put down for drugs that have been dropped by a major pharma company, …


Cancer Research UK agrees largest drug discovery collab to date

December 15, 2017
Medical Communications, Research and Development Cancer Research UK, Celgene, biotech, drugs, pharma, pharmaceutical

Cancer Research UK has announced that its subsidiary, Cancer Research Technology (CRT), and Celgene have agreed a drug discovery collaboration. …


Celgene hikes price of Revlimid to mask poor Q3 results

October 27, 2017
Medical Communications, Sales and Marketing Celgene, Revlimid, biotech, drugs, pharma, pharmaceutical

Celgene posted its Q3 results and investors did not react well – shares plunged 16% immediately, after the biotech cut …

Latest content